15 results about "Viral protease" patented technology

Vaccine compositions for protecting a subject against diseases caused by viral pathogens of the Picornaviridae family are disclosed. These vaccines comprise nucleic acids encoding the capsid polyprotein (P1 polyprotein) mixed with the viral 3C protease that processes the P1 polyprotein, and encapsulated within nanoparticle carriers. Methods of preventing, reducing, inhibiting, or delaying the symptoms of an infection caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject are provided. Methods of making the vaccines are also described.

The present application discloses an antiviral fusion protein. Specifically, the present application provides an antiviral fusion protein, which comprises a cell death inducing domain (lethal domain), a domain inhibiting the activity of the lethal domain (inhibitory domain) and a protease recognition sequence capable of removing or destroying the function of the inhibitory domain; the fusion protein has the activity of inducing cell death after being cut by a specific viral protease, thereby killing the cells infected by the virus in a targeted manner. The present application also discloses a programmable method for inducing the death of virus-infected cells, which comprises transferring the above-mentioned fusion protein or nucleic acid into cells so that the cells die before replication and assembly after being infected by the virus, thereby achieving timely and effective elimination of the virus.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The present invention pertains to compounds that inhibit Flavivirus NS2B-NS3 proteases and are potent and selective inhibitors of the West Nile virus and Zika virus. The compounds of the invention can be used alone or in combination with other agents to treat infections caused by these viruses. Additionally, the invention relates to pharmaceutical compositions containing these compounds.

Crystallization and Use of Viral Protease Inhibitors. Specifically, this invention relates to the crystalline form of Compound 1 or a pharmaceutically acceptable salt thereof and its use. The invention also relates to methods for preparing the crystalline form, as well as compositions containing the crystals and pharmaceutical compositions. The crystalline form is stable, has high yield, involves mild crystallization conditions, is suitable for industrial production, and can fully meet the requirements of the pharmaceutical industry.

Provided is a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, and use thereof for preparing an antiviral protease inhibitor drug.

Provided herein are compositions and methods that allow for controlled interaction between a target protein and a polypeptide to which a binding protein is fused. Compositions and methods utilize a target protein that binds to the hepatitis C virus protease inhibitor glaprevir to form a complex, and a Tn3 binding protein that specifically binds to the complex. The target protein is or is derived from a viral protease, such as an HCV NS3 / 4A protease.

The present document describes compounds that are inhibitors of coronavirus proteases, and more particularly to compounds that are inhibitors of SARS-CoV-2 viral proteases. Also, the present document describes methods and uses of the compounds for the treatment or prevention of viral infection, such as SARS-CoV-2 infections, in a subject in need of treatment.

The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The present application provides a preparation (pharmaceutical composition) containing an uracil derivative showing coronavirus 3CL protease inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof as an effective ingredient. In addition, the present application provides a crystal of an uracil derivative showing coronavirus 3CL protease inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof.

The application discloses a compound with a structural formula I, wherein the compound has good 3CL protease inhibitory activity, has significant proliferation inhibitory activity on virus-infected cells, and has potential application value in treating diseases related to virus infection. The compound has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential drug compound.

The invention relates to protease, in particular to an HRV3C virus protease mutant and application thereof. The HRV3C protease variant is characterized in that the amino acid sequence of the HRV3C protease variant is as shown in SEQ ID NO. 4. The HRV3C protease mutant provided by the invention is not easy to aggregate and precipitate, tolerant to imidazole, obviously higher in thermal stability and yield than a wild type, and equivalent to the wild type in activity.

The present invention relates to compounds that have new designs for viral protease inhibitors. The warheads and P1 residues of the compounds can have structures that offer improved properties. The invention also relates to compositions and medical uses of such compounds, and to intermediate products that are useful for the provision of such compounds.

The invention discloses a gossypol derivative, a preparation method thereof and application of the gossypol derivative in preparation of a coronavirus 3CL protease inhibitor, and belongs to the field of medical chemistry. The novel gossypol derivative is obtained by carrying out structural modification on gossypol by utilizing isocyanate or a primary amine compound. Preliminary tests show that the gossypol derivative obtained by the method can effectively block RNA (Ribonucleic Acid) replication and transcription processes by inhibiting 3CLpro so as to block virus proliferation, exert an anti-coronavirus effect and remarkably reduce the activity of 3CLpro protease, is long in acting time, strong in drug effect and not easy to generate drug resistance, can be used for preventing and treating coronavirus infection, and has a good application prospect. Therefore, the compound can be used for preparing medicines for preventing, treating and diagnosing coronavirus.